Trial Profile
Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms VESTA
- Sponsors AbbVie; AbbVie Germany
- 26 Aug 2021 Primary endpoint has not been met. (Overall Survival (OS) in current smokers.), as per Results published in the Journal of Clinical Oncology
- 26 Aug 2021 Results assessing therapeutic benefit of adding veliparib to first-line chemotherapy in In current smokers with advanced squamous Cell lung cancer, published in the Journal of Clinical Oncology
- 16 Oct 2019 Planned number of patients changed from 970 to 975.